EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

SEOM clinical guidelines on venous thromboembolism (VTE) and cancer (2023)

Laura Ortega Morán, Francisco José Pelegrín Mateo, Rut Porta Balanyà, Jacobo Rogado Revuelta, Silverio Ros Martínez, José Pablo Berros Fombella, Elena María Brozos Vázquez, Natalia Luque Caro, José Muñoz Langa, Mercedes Salgado Fernández

Clinical and Translational Oncology · 07.08.2024 · 26 (11) · 2877-2901

DOI: 10.1007/s12094-024-03605-2 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Clinical and Translational Oncology, online erschienen am 07.08.2024. Verfasst von Laura Ortega Morán und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain. lauraortegamoran@gmail.com. Hauptthemen laut MEDLINE: Venous Thromboembolism, Neoplasms, Anticoagulants, Medical Oncology. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Spanish Society of Medical Oncology (SEOM) last published clinical guidelines on venous thromboembolism (VTE) and cancer in 2019, with a partial update in 2020. In this new update to the guidelines, SEOM seeks to incorporate recent evidence, based on a critical review of the literature, to provide practical current recommendations for the prophylactic and therapeutic management of VTE in patients with cancer. Special clinical situations whose management and/or choice of currently recommended therapeutic options (low-molecular-weight heparins [LMWHs] or direct-acting oral anticoagulants [DOACs]) is controversial are included.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous ThromboembolismNeoplasmsAnticoagulantsMedical OncologyHumansHeparin, Low-Molecular-WeightSocieties, Medical

Stichwörter der Autor:innen

AnticoagulationCancerDirect oral anticoagulantsGuidelinesLow-molecular-weight heparinsVenous thromboembolism

Substanzen

AnticoagulantsHeparin, Low-Molecular-Weight

Autor:innen und Institutionen

  • Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain. lauraortegamoran@gmail.com.
  • Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Hospital Universitari Dr. Josep Trueta, ICO Girona, Girona, Spain.
  • Hospital Universitario Infanta Leonor, Madrid, Spain.
  • Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
  • Hospital Universitario San Agustín, Avilés, Asturias, Spain.

Zitieren

APA

Morán, L. O., Mateo, F. J. P., Balanyà, R. P., Revuelta, J. R., Martínez, S. R., Fombella, J. P. B., Vázquez, E. M. B., Caro, N. L., Langa, J. M., & Fernández, M. S. (2024). SEOM clinical guidelines on venous thromboembolism (VTE) and cancer (2023). Clinical and Translational Oncology, 26(11), 2877-2901. https://doi.org/10.1007/s12094-024-03605-2

Vancouver

Morán LO, Mateo FJP, Balanyà RP, Revuelta JR, Martínez SR, Fombella JPB, et al. SEOM clinical guidelines on venous thromboembolism (VTE) and cancer (2023). Clinical and Translational Oncology. 2024;26(11):2877-2901. doi:10.1007/s12094-024-03605-2

BibTeX
@article{Morn2024,
  author = {Morán, Laura Ortega and Mateo, Francisco José Pelegrín and Balanyà, Rut Porta and Revuelta, Jacobo Rogado and Martínez, Silverio Ros and Fombella, José Pablo Berros and Vázquez, Elena María Brozos and Caro, Natalia Luque and Langa, José Muñoz and Fernández, Mercedes Salgado},
  title = {SEOM clinical guidelines on venous thromboembolism (VTE) and cancer (2023)},
  journal = {Clinical and Translational Oncology},
  year = {2024},
  volume = {26},
  number = {11},
  pages = {2877--2901},
  doi = {10.1007/s12094-024-03605-2}
}
Kostenlos starten →